NCT04434560View on ClinicalTrials.gov

Neoadjuvant Immunotherapy in Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

June 17, 2021

Study Completion Date

June 17, 2021

Conditions
Brain Metastases, Adult
Interventions
DRUG

Nivolumab

Nivolumab will be given at the FDA-approved dose of 3 mg/kg.

DRUG

Ipilimumab

Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Duke University

OTHER

lead

Sarah Sammons, MD

OTHER